标题
The therapeutic potential of PROTACs
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume -, Issue -, Pages -
出版商
Informa UK Limited
发表日期
2020-10-21
DOI
10.1080/13543776.2021.1840553
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
- (2020) Thomas L. Gonzalez et al. BREAST CANCER RESEARCH AND TREATMENT
- FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice
- (2020) Hongying Gao et al. Protein & Cell
- Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
- (2019) Jiantao Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)
- (2019) William T. McElroy EXPERT OPINION ON THERAPEUTIC PATENTS
- Targeting Nuclear Receptors with PROTAC degraders
- (2019) John J. Flanagan et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation
- (2019) Lijie Peng et al. ACS Medicinal Chemistry Letters
- Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation
- (2019) Hong Chen et al. BIOORGANIC CHEMISTRY
- Selective oestrogen receptor degraders in breast cancer
- (2019) Andrea Gombos CURRENT OPINION IN ONCOLOGY
- Bromodomains: a new target class for drug development
- (2019) Andrea G. Cochran et al. NATURE REVIEWS DRUG DISCOVERY
- PROTACs– a game-changing technology
- (2019) Markella Konstantinidou et al. Expert Opinion on Drug Discovery
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
- (2019) Concepción Sánchez-Martínez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A kinase-independent role for CDK8 in BCR-ABL1+ leukemia
- (2019) Ingeborg Menzl et al. Nature Communications
- Design, synthesis, and biological evaluation of small molecule PROTACs for potential anticancer effects
- (2019) Yang Da et al. MEDICINAL CHEMISTRY RESEARCH
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Modulating the masters: chemical tools to dissect CBP and p300 function
- (2018) Meghan E Breen et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers
- (2018) Luping Qiu et al. PLoS One
- Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8
- (2018) John M. Hatcher et al. ACS Medicinal Chemistry Letters
- Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
- (2018) Dazhi Liu et al. Therapeutics and Clinical Risk Management
- Moonlighting with WDR5: A Cellular Multitasker
- (2018) Alissa Guarnaccia et al. Journal of Clinical Medicine
- Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807
- (2018) David T. Chien et al. JOURNAL OF ALZHEIMERS DISEASE
- Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
- (2018) E. David Crawford et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
- (2018) Philipp M. Cromm et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer
- (2018) Kebin Lu et al. Frontiers in Oncology
- A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells
- (2016) Christopher J. Matheson et al. ACS Chemical Biology
- The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain
- (2016) Sarah E. Skerratt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer
- (2016) Narsis Attar et al. Cold Spring Harbor Perspectives in Medicine
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- The MYC-WDR5 Nexus and Cancer
- (2015) L. R. Thomas et al. CANCER RESEARCH
- Alike but Different: RAF Paralogs and Their Signaling Outputs
- (2015) Enrico Desideri et al. CELL
- Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
- (2015) Donald P. McDonnell et al. JOURNAL OF MEDICINAL CHEMISTRY
- RAF inhibitors that evade paradoxical MAPK pathway activation
- (2015) Chao Zhang et al. NATURE
- A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease
- (2015) Trevor Dale et al. Nature Chemical Biology
- FAK signaling in human cancer as a target for therapeutics
- (2015) Brian Y. Lee et al. PHARMACOLOGY & THERAPEUTICS
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
- (2014) Stuart W. J. Ember et al. ACS Chemical Biology
- RIP kinases: key decision makers in cell death and innate immunity
- (2014) F Humphries et al. CELL DEATH AND DIFFERENTIATION
- Mechanisms of protein-folding diseases at a glance
- (2014) J. S. Valastyan et al. Disease Models & Mechanisms
- Understanding the Roles of FAK in Cancer
- (2014) Hyunho Yoon et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders
- (2014) Divya Chaudhary et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3
- (2014) Asli Muvaffak et al. MOLECULAR CANCER RESEARCH
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- EZH2 as a potential target in cancer therapy
- (2014) Michael T McCabe et al. Epigenomics
- B-Raf and the inhibitors: from bench to bedside
- (2013) Tiangui Huang et al. Journal of Hematology & Oncology
- Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
- (2012) Irene Kuter et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
- (2012) Dennis L. Buckley et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The Central Theme of Parkinson’s Disease: α-Synuclein
- (2012) Mehmet Ozansoy et al. MOLECULAR NEUROBIOLOGY
- Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors
- (2011) Hongbo Zeng et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
- (2011) P. C. De Witt Hamer et al. CLINICAL CANCER RESEARCH
- Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
- (2011) Chuangxing Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of Diaryl Ether-Based Ligands for Estrogen-Related Receptor α as Potential Antidiabetic Agents
- (2011) Raymond J. Patch et al. JOURNAL OF MEDICINAL CHEMISTRY
- PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments
- (2010) Isabelle Tanjoni et al. CANCER BIOLOGY & THERAPY
- Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant
- (2010) Wei-Sheng Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Mechanisms of tau-induced neurodegeneration
- (2009) Khalid Iqbal et al. ACTA NEUROPATHOLOGICA
- SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
- (2009) Andrew Conroy et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
- (2008) Daniel G Healy et al. LANCET NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now